An Approach to Early Detection of Significant Cancers
|
|
- Aron Stafford
- 6 years ago
- Views:
Transcription
1 An Approach to Early Detection of Significant Cancers FDUS E. David Crawford, M.D. University of Colorado Denver Aurora, CO
2 AUA State of Art 2
3 WSJ
4 Recent Advances in Prostate Cancer: E. David Crawford 1) PCMs (Prostate Cancer Markers): Molecular Markers and Genomic Assays 2) Multiple new therapeutics with different mechanisms of action advanced prostate cancer 4
5 Prostate Cancer Detection Challenges 1) Improve the interpretation of PSA, thus allow Primary Care Physicians to enhance referral efficiency for Urology evaluation 2) A test which will decrease unnecessary negative re-biopsies and enhance detection 3) A test to enhance risk stratification of newly diagnosed PCa patients who are best suited for surveillance vs interventional therapy 5
6 PCMs Tissue Blood What is a biomarker? A molecule that can be found in blood, 3ssue or body fluids that is a sign of a normal or abnormal process Urine 6
7 PCM Buckets
8 Message from USPSTF And Other Organizations Following the Lead PSA screening is a D recommendation Physicians should not order PSA screening unless they are prepared to engage in shared decision making that enables an informed choice by patients Supported by AAFP AAFP recommends against performing PSAbased screening for prostate cancer in asymptomatic men What to do? Moyer VA, et al. Ann Intern Med Jul 17;157(2): AAFP, USPSTF Issue Final Recommenda3on Against Rou3ne PSA- based Screening for Prostate Cancer 8
9 Prostate Cancer: Current Needs Refine PSA Increase the likelihood of an initial positive biopsy Reduce unnecessary repeat biopsies, enhance distinguishing benign from malignant disease Stratify low risk from higher risk cancers Will PCMs (Prostate Cancer Markers) improve our management? 9
10 Change is Imperative! No One Size Fits All Genomics Proteomics Metabolomics Precision medicine Personalized diagnosis and therapy 10
11 What Percent of all of the PSA s ordered in the US are by Urologists 1. 6% 2. 25% 3. between 40-60% 4. around 70% 11
12 Who is Ordering PSA Tests in United States? 1.3 We need to educate those who are ordering and interpre3ng PSAs Internal Medicine Family Medicine Urology Hem/Onc 64.9% 23.7% 6.1% 1.3% Aslani A, et al. J Urol. 2013;do: /j.juro
13 Ways Forward Educate those who order PSAs PCPs Define a PSA level with little risk (age, family history, prostate gland volume, symptoms, DRE) Identify those who need further evaluation by a Urologist 13
14 Defining PSA Levels and Improving Performance Patients and Methods: 350,000 HMO-Henry Ford System Men in system Initial PSA between 1-5ng/ml Minimum 5 years follow-up No 5 ARIs Results: Mean age -55 years Mean PSA 1.0 African American 29% Detected Cancer: 2% 21,502 men eligible 14
15 5-year Diagnosis Rates Based on Initial PSA Level Percent developing prostate cancer 12% 10% 8% 6% 4% 2% 0% Overall Study Popula<on (21,500) 0.51% PSA < 1.5ng/mL 15- fold increase in risk 7.85% PSA 1.5-4ng/mL African Americans 19- fold increase in risk 10.39% Receiver Opera<ng Characteris<c Curve for All Pa<ents Percent developing prostate cancer Maximum sensi3vity and specificity at PSA 1.5 ng/ml Es3mated Area C= Specificity A first PSA test threshold of ng/ml, represents the Early- Warning PSA Zone Pa<ents with PSA 1.5 ng/ml have an increased risk of developing PC Crawford ED, et al. BJU Int. 2011;108(11):
16 Serum PSA 1.5ng/mL Predicting Enlargement & Risk of Progression Prostate volume (ml) PSA of 1.5 surrogate for enlarged prostate 65 Age (years) Risk of progression* Adapted from Roehrborn CG et al. Urology. 1999;53: *Crawford ED et al. J Urol. 2006;175: Serum PSA (ng/ml) 16
17 Natural History of Untreated BPH Progression Male patient, age 55 years: symptomatic EP, PSA = 1.5 ng/ml, negative for prostate cancer Age 55 yrs 60 yrs 65 yrs 70 yrs PV 30 ml >40 ml >50 ml >61 ml PSA 1.5 ng/ml Figure based on Roehrborn C, et al. J Urol. 2000;163:13 20.
18 Using PSA as an Aid to Diagnose BPH The PSA value is more accurate than a DRE in estimating prostate size when trans-rectal ultrasound is not available 1 The DRE tends to underestimate prostate size, and the degree of underestimation correlates with increasing prostate size 1 PSA 1.5 ng/ml suggests a prostate volume >30 ml 2 Prostate volume (ml) Serum PSA (ng/ml) Age (years) Error roughly 5 ml Figure adapted from Roehrborn C, et al. Urology. 1999;53: Bosch J, et al. Eur Urol. 2004;46: Kaplan S. Weill Medical College of Cornell University Reports on Men s Urologic Health. 2006;1(1):1 8.
19 A Practical Algorithm for the Treatment of BPH in Primary Care Man >50 years old presents with urinary symptoms No Determine if patient has Enlarged Prostate ( 30 ml): DRE PSA 1.5 ng/ml Yes Treat symptoms Treat symptoms and reduce prostate size -blocker 5ARI Combination 5ARI plus -blocker Reassess periodically Adapted from Figure 3, entitled Practical Algorithm for the treatment of EP in primary care: in Kaplan S. Weill Medical College of Cornell University Reports on Men s Urologic Health.
20 Prostate Size and Urinary Symptoms 20
21 Early Detection A Way Forward PSA treated like other lab tests, lipids, electrolytes, weight, and BP-routine Informed decision when tests are abnormal 70% of men require no discussion-based on our screening data on 150,000 men Men s health broader issue > 1.5 ng/ml surrogate for BPH, Prostatitis, Prostate Cancer Roehrborn CG et al. Urology. 1999;53:
22 Pa3ent Presents for Screening (PCP) PSA Test PSA < 1.5 PSA > 1.5 Do Nothing Repeat PSA Provider CaP Evalua.on Algorithm with PCMs PCP Evalua3on Urologist Evalua3on PCMs Biopsy Result Final Recommenda3on Urologist Repeat DRE and PSA Norm al Regular Screening Abnorma l Monitor Nega3ve Biopsy * Select MDx PCA3 PHI 4K Posi3ve Who to biopsy? Know Error specimen provenance Adopted from Crawford et al. (PMID: ) Who to rebiopsy? Avoid Rebiopsy Confirm MDx PCA3 Select MDx 4K PCMT Rebiopsy Indeterminat e ASAP HGPIN Atypia Ac3ve Surveillance *Consider Targe3ng MRI/US Fusion Biopsy Oncotype Dx Prolaris PTEN- ERG ProMark Who to treat? Indolent vs aggressive cancer? Interven3on - RP - Cryo - IMRT - ADT - Brachy Decipher Prolaris?AR- V7? HSD3B1 further therapy?
23 Prostate Cancer Diagnostic Pathway: Role for Genomic Tests and Biomarkers Pa3ent Presents SCREENING PSA Test PSA < 1.5 PSA > 1.5 Phi 4K SelectMDx PCA3 Urologist Repeat PSA/DRE Conduct Biopsy Normal Abnormal Monitor Nega3ve ConfirmMDx PCA3 4K phi Avoid Re- biopsy Re- biopsy Copyright Neal Shore, MD 2015 Indeterminate ASAP HGPIN ATYPIA Re- Bx Ac3ve Surveillance Posi3ve OncotypeDX ProMark PTEN / ERG Prolaris Indolent vs. aggressive cancer Interven3on Decipher Prolaris Know Error 23 CRPC CTC s AR- V7
24 Prostate Cancer Diagnostic Pathway: Role for Biomarkers Pa3ent Presents SCREENING PSA Test PSA < 1.5 PSA > 1.5 PHI 4K score PHI SELECTMDx PCA3 Urologist Repeat PSA/DRE Conduct Biopsy Normal Abnormal Monitor 24
25 New Paradigm HIGH false-positive rate leading to unnecessary biopsy REDUCE over-diagnosis of men with GS 6 cancer REDUCE over-treatment of non-lethal disease 25
26 The Goal in 2016 Gleason 6 Ac<ve Surveillance
27 PSA Performance Beckman Coulter phi PSA Isoforms FDA Approved, 2012 For men with tpsa between 2 10 ng/ml and non suspicious DRE for PCa tpsa fpsa [- 2] propsa Posi<ve biopsy (%) <30 n= n= n= n= n=86 83 >70 n= >80 n=69 ([- 2] propsa/fpsa)* tpsa phi score phi 27
28 PCA3 Prostate tumor Marker release from tumor DRE Cell shedding Blood sample Urine sample Measure PSA protein in serum PCA3 is FDA approved and has CMS reimbursement Adapted from Marks LS, Rev Urol. 2008;10(3): Measure PCA3 and PSA mrna from cells PCA3 score = PCA3/PSA mrna x
29 Percent of Men with Positive Biopsy by PCA3 Score First Biopsy 80% 70% PCA3 Score (95% CI) 60% 50% 40% 30% 20% 10% 0% < >100 PCA3 Score (n=1914) Crawford ED et al. J Urol Nov;188(5):
30 PCA3: Report PROGENSA PCA3 Performing Site: Clinical Lab PATIENT INFORMATION SPECIMEN ID: 15AGS Metamark, Inc Metamark, Inc. 100 Kestrel Drive, Collegeville, PA Phone PATIENT INFORMATION SPECIMEN ID #: XXXXXXXXX PHYSICIAN Name: DOB: Patient #: Patient Name XX/XX/XXXX XXXXXXXXX Date Collected: Date Received: Date Reported: 4/28/2015 4/29/2015 4/30/2015 Primary Physician: Client: Client #: Physician Name XXXXXXXXXX XXXXXX 10 PROGENSA PCA3 DIAGNOSIS 1. A negative score is associated with a decreased likelihood of a positive biopsy for prostate cancer. 2. An adequate amount of PSA RNA was detected in the urine sample. The Progensa PCA3 test was developed and its performance characteristics determined by Hologic, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Metamark is certified under Clinical Laboratory Improvements Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing. REFERENCES Progensa PCA3 Assay Package Insert Rev. B. Hologic Inc. TEST CHARACTERISTICS Due to normal assay variability, specimens with PCA3 scores near the cut-off of 25 (i.e ) could yield a different overall interpretation of positive or negative upon repeat testing. PCA3 scores in the range from 18 to 31 should, therefore, be interpreted with caution. The testing method is target capture, transcriptionmediated amplification (TMA) and hybrid protection assay (HPA), manufactured by Hologic, Inc and performed using the Hologic, Inc Progensa assay kit. Dwight Mirmow, MD Final Report Electronically Signed on 4/30/2015 at 2:56 PM CPT Codes: _ CLIA #: 39D Copyright 2014 Metamark, Inc. All rights reserved 30
31 PSA PERFORMANCE : 4Kscore Prostate Bx for aggressive CaP 4Kscore Prostate Cancer Test Prostate cancer test Based on the following panel of kallikrein markers: Total PSA Free PSA Intact PSA Human Kallikrein 2 (HK2) + Age, DRE, and prior biopsy status 31
32 4Kscore test: Reports individual % risk of aggressive prostate cancer if prostate biopsy was performed The patient s 4Kscore Test result is 5% At a 4Kscore Test result of 5%, about 1 in 20 men biopsied would have high-grade prostate cancer. 4Kscore Test Result 1% 5% 10% 15% 20% 25% 30% 40% 50% 60% 70% 80% 90% 95% = 95% chance that the biopsy does not find a high-grade prostate cancer < 2 Number of men to biopsy to find one high-grade prostate cancer = 5% chance that the biopsy finds a high-grade prostate cancer. 4Kscore = Posi3ve Predic3ve Value 32
33 4K Medicare Letter Conclusion low grade prostate cancer (not on AS); there is significant difficulty equating the model used in the Swedish study to the presently proposed formula; and the incidence of clinically diagnosable prostate cancer in patients with low risk by the model/algorithm at 10 years is very concerning. Consequently, due to significant issues with assay validation and absence of clinical utility, 4Kscore testing is not reasonable and necessary and is not covered by Medicare. 33
34 Improved Risk Stratification for Clinically Significant Cancer Increased Risk for GS 7 PCa Consider Biopsy Routine Screening Elevated PSA, Abnormal DRE Select MDx Very Low Risk for GS 7 PCa Avoid Biopsy For pa<ents being considered for ini<al prostate biopsy Iden3fy men at high risk for aggressive cancer Assay performed on non- invasive, urine sample Very Low Risk 99.6% NPV for GS 8 98% NPV for GS 7 34
35 SelectMDx for Prostate Cancer Clinical Validation of a Risk Profile for the Detection of High Grade Cancer SelectMDx Risk Profile: Strongest predictor of high- grade disease 98% NPV for GS 7 cancer AUC of 0.89 (95% CI ) European Urology 2016 Van Neste et al., European Urology
36 SelectMDx Performance Outperforms PCA3 & PCPT Risk Calculator for Detection of High Grade Cancer ROC Curve for Clinically Significant Cancer Correlation with Gleason Score Sensi3vity SelectMDx 0.77 PCPTRC 2.0 SelectMDx Risk Profile p< p< PCA Specificity No PCa GS 6 GS 7 Van Neste L, Hendriks RJ, Schalken JA et al; Detec3on of High- grade Prostate Cancer Using a Urinary Molecular Biomarker Based Risk Score, Eur Uro 2016 Accepted 36
37 Improves the Identification of Men for Prostate Biopsy: High Risk Increased risk for aggressive cancer Men who may benefit from biopsy Very Low Risk 98% NPV for aggressive cancer May avoid biopsy Return to routine screening Patient Report Sample Sample Patient Report Patient Name: Ken Sample Date of Birth: 12/27/1953 MRN/Patient#: PSA: DRE: Patient Result: 8 ng/ml Normal The SelectMDx test result for this patient indicates a 85% likelihood of detecting prostate cancer, with a 50% probability for Gleason score 7, when performing a standard 12-core TRUS guided biopsy. Test Description: Disclaimer: MDxHealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists as an accredited laboratory to perform high complexity clinical testing. The SelectMDx for Prostate Cancer test was developed and its performance characteristics determined by MDxHealth. The test is intended for use as an aid to clinicians for patient management decisions about the need for a prostate biopsy on men with clinical factors suggesting an increased risk for prostate cancer. Use outside of this indication has not been validated by MDxHealth. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician and relevant guidelines on the decision for biopsy. MDxHealth is certified by DEKRA for ISO 9001:2008 Quality Management System. This test was performed by MDxHealth Inc.,15279 Alton Parkway, Suite 100, California CLIA# 05D ; CAP# General information about SelectMDx for Prostate Cancer can be found at If you have any questions regarding this report, please contact MDxHealth Client Services at or clientservices@mdxhealth.com. Jess Savala, Jr., MD, Laboratory Director PATIENT Specimen#: Collection Date: 11/05/2015 Received Date: 11/07/2015 Report Date: 11/09/2015 Specimen Type: SPECIMEN Urine MDxH Accession#: PR Likelihood of prostate 85% cancer upon biopsy 50% Physician: Account: ACCOUNT Randolph Smith, MD. Urology Associates Address: Alton Drive Suite 100 City/State/Zip: Irvine, CA Likelihood of detecting Gleason score 7 SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on urine specimens collected immediately following DRE from patients who are being considered for prostate biopsy. The test measures the urinary mrna levels of the DLX1 and HOXC6 biomarkers to aid in patient selection for prostate biopsy. Higher levels of DLX1 and HOXC6 mrna are associated with an increased probability for Gleason score 7 (GS 7) prostate cancer. A logistic regression model combining DLX1 and HOXC6 mrna levels with established clinical risk factors, including PSA, prostate volume, DRE, family history and age, is used to estimate the likelihood of detecting GS 7 prostate cancer upon biopsy, with an area under the curve (AUC) of 0.88 (95% CI: ), in addition to the likelihood of no cancer or GS 6 disease. Performance is based on the presence of all relevant data elements; if all data are not available, or 5α-reductase inhibitors (5-ARIs) have been administered to decrease serum PSA values, results should be interpreted with caution and AUC of the test may vary. References: 1) Leyten et al; Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res Jul 1;21 (13): ) Hamid et al; The role of HOXC6 in prostate cancer development. The Prostate Dec;75 (16): Alton Parkway Suite 100 Irvine, CA P: MDxHealth, Inc., All Rights Reserved. Inc. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Leyten et al. Clin Cancer Res,
38 SelectMDx for Prostate Cancer Offers non-invasive, office based sample collection Improves detection of high grade cancer with patient-specific risk profile Helps identify men at Very Low Risk for aggressive cancer Outperforms standard clinical risk factors and other biomarkers alike Reasonable price offers cost-effective option to guide MRI & biopsy 38
39 Gleason 6 Ac<ve Surveillance
40 Tests in Bucket of who to biopsy 4 0 Assay Characteris<cs Company Beckman Coulter Opko Hologic MDxHealth Specimen Blood Blood Urine Urine Methodology Immuno assay Immuno assay qpcr qpcr 3 Protein biomarkers tpsa and fpsa, propsa 4 kallikriens biomarkers mrna test, 1 biomarker PSA, fpsa, Intact PSA, HK- 2 PCA3 2 mrna Biomarkers DLX1, HOXC6 Regulatory FDA/CE LDT/CLIA/CE FDA/CE LDT/CLIA/CE List price ($) $499 $1,900 $500 $500 Assay Performance (AUC) AUC 0.73 AUC 0.82 AUC 0.68 AUC 0.89 Comments Requires Phlebotomist 1) PCEC 2015, 2) Curr Opin Oncol May ; 26(3): Requires Phlebotomist & Centrifuge Urine Sample - In Office Procedure Urine Sample - In Office Procedure
41 Family Prac33oner Shared care Urologist Consider Tx PSA 5 years PSA <1.5 GS GS 6 or 3+4 Consider Tx High Risk TRUS Bx Genomic Markers Rou<ne Lab/PSA - Low Risk PSA >1.5 High Risk - ConfirmMDx + Ac<ve Surveillance PHI, MP MRI Consider referral to Urologist SelectMDxPCA3,4K Low Risk Copyright: E.D.Crawford
42 101 men with negative mpmri and correlation with RRP 42
43
44 Dare We Go Back to the Pre-PSA Era? With the introduc3on of PSA tes3ng, death from prostate cancer was reduced by 20%, whereas metasta3c disease was reduced by nearly half Welch, nejm ;18. Gomella, LG Celebra3ng the Death of PSA screening CJU December 2011
45 A Decision Aid for the Task Force
46 How to save the baby: screen smarter Start earlier Screen less frequently if baseline is low Focus on populations at highest risk Screen for high-risk prostate cancer, don t over-treat low-risk disease Embrace active surveillance Fix incentives Refer early and wisely Change nomenclature? Continue to develop novel biomarkers
47 Conclusions Screening saves lives, period. The USPSTF analysis downplays benefits, overestimates harms, and is predicated on far too short of a time horizon. Overtreatment is without question a major public health problem, and we have to fix it. But the answers lie in smarter screening and better treatment decisions, not in wholesale cessation of screening. To own the truth, own the data
48 Thank you
The Who s of Genomic Markers: Whom to Biopsy?
The Who s of Genomic Markers: Whom to Biopsy? 1.15.17 7:20-7:40 AM E. David Crawford, M.D. Professor of Surgery/Urology/ Radiation Oncology University of Colorado WSJ 5.10.16 2 Recent Advances in Prostate
More information#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats
Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7
More informationShould A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?
Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationMDxHealth. Acceleration of payor coverage ConfirmMDx. Research Note.
Research Note MDxHealth Acceleration of payor coverage ConfirmMDx Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationThe 4Kscore A Precision Test for Risk of Aggressive Prostate Cancer. Reduce Unnecessary Invasive Procedures And Healthcare Costs
The 4Kscore A Precision Test for Risk of Aggressive Prostate Cancer Reduce Unnecessary Invasive Procedures And Healthcare Costs PSA Lacks Specificity for Aggressive Prostate Cancer Abnormal PSA leads to
More information4Kscore. A Precision Test for Risk of Aggressive Prostate Cancer
4Kscore A Precision Test for Risk of Aggressive Prostate Cancer How to Evaluate Risk for Prostate Cancer? PSA is a good screening tool But abnormal PSA leads to over 1 million prostate biopsies each year
More information..biomarkers, running the gauntlet..
The long and winding round for the clinical introduction of a biomarker Molecular diagnostic of prostate cancer based on non invasive liquid biopsies..biomarkers, running the gauntlet.. Prof dr Jack A
More informationThe Role of PCP in Prostate Cancer Screening Beaver Creek Ma< T. Rosenberg
The Role of PCP in Prostate Cancer Screening Beaver Creek 2017 Ma< T. Rosenberg A Cri@cal Look at the Historical Flow Pa@ent concern Office visit History DRE PSA Biopsy Specimen with pathologist Too Many
More informationPersonalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017
Personalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017 Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops Osher
More informationMAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE. The Progensa PCA3 test
MAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that gives you the information you need to determine if
More informationMP Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Medical Policy MP 2.04.33 BCBSA Ref. Policy: 2.04.33 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section: Medicine Related Policies 2.04.111 - Gene Expression Analysis for Prostate Cancer Management
More informationAVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY. The Progensa PCA3 test
AVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that helps you and your doctor decide if a repeat biopsy
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationGenetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Policy Number: 2.04.33 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationDebate: Genetics and Genomics should be used ONLY for re-biopsy
Debate: Genetics and Genomics should be used ONLY for re-biopsy Larry Goldenberg, CM, OBC, MD, FRCSC Professor, UBC Dept of Urologic Sciences Director of Development and Supportive Care, Vancouver Prostate
More informationGenetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Policy Number: 2.04.33 Last Review: 7/2018 Origination: 7/2014 Next Review: 7/2019 Policy Blue Cross and Blue
More informationExploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies
Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic and Protein Biomarkers for the Diagnosis Page 1 of 41 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Genetic and Protein Biomarkers for the Diagnosis
More informationMP Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Medical Policy MP 2.04.33 BCBSA Ref. Policy: 2.04.33 Last Review: 11/30/2017 Effective Date: 11/30/2017 Section: Medicine End Date: 02/14/2019 Related Policies 2.04.111 - Gene Expression Analysis for Prostate
More informationA biopsy can be avoided in patients with positive DRE and negative MRI. Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.
A biopsy can be avoided in patients with positive DRE and negative MRI Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.C, Afula, Israel Financial and Other Disclosures Off-label use of drugs,
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationCorporate Medical Policy
Corporate Medical Policy Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_and_protein_biomarkers_for_diagnosis_and_risk_assessment_of_prostate_cancer
More informationHow will new biomarkers change prostate cancer management
How will new biomarkers change prostate cancer management Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics BAUS Section of Oncology Annual Meeting Cardiff, UK 15 November
More informationGene-Based Tests for Screening, Detection, and/or Management of Prostate Cancer
Medical Policy Manual Genetic Testing, Policy No. 17 Gene-Based Tests for Screening, Detection, and/or Management of Prostate Cancer Next Review: September 2019 Last Review: December 2018 Effective: January
More informationPathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers
Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers M. Scott Lucia, MD Professor and Vice Chair of Anatomic Pathology Chief of Genitourinary and Renal Pathology Dept. of
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationGenomic biomarkers in prostate cancer
Review Article Genomic biomarkers in prostate cancer Zachary Kornberg 1, Matthew R. Cooperberg 2, Daniel E. Spratt 3, Felix Y. Feng 1 1 Department of Radiation Oncology, 2 Department of Urology, UCSF Helen
More informationProtein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer
Medical Policy Manual Laboratory, Policy No. 69 Protein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer Next Review: October 2018 Last Review: December 2017 Effective: January
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationWhy 1.5 is the New 4.0 for the PCP? Ma8 T. Rosenberg, MD A Concerned Family PracFFoner Jackson, MI
Why 1.5 is the New 4.0 for the PCP? Ma8 T. Rosenberg, MD A Concerned Family PracFFoner Jackson, MI PSA Screening RecommendaFons of Major SocieFes Organiza(on Who To Screen Screening Interval USPSTF, 2012
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Diagnosis and monitoring of prostate cancer: PROGENSA PCA3 assay and the Prostate Health Index (PHI) This overview summarises the key issues for the Diagnostics
More informationResolving the PSA testing controversy. Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg
Resolving the PSA testing controversy Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg Professor Villis Marshall AC Introduc)on Guidelines aim to inform tes)ng for the
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationPredicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort MACIEJ SALAGIERSKI 1, PETER MULDERS 2 and JACK A. SCHALKEN 2 1 Urology Department, Medical University of Łódź, Poland;
More informationMr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015
www.drjeremygrummet.com.au www.aua.com.au Mr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015 The dilemma Most men die with prostate cancer rather than
More information10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018
Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Elevated PSA and/or nodule on digital rectal examination Prostate biopsies If initial
More informationTRUS Guided Transrectal Prostate Biopsy
TRUS Guided Transrectal Prostate Biopsy Will this be a technique of the past? Christopher Porter MD FACS, Virginia Mason Medical Center, Seattle Outline Will this book be obsolete? Old school Elevated
More informationEvaluation of the Cost-Effectiveness of Novel Tests in the Screening and Diagnostic Phases of Prostate Cancer Compared to Current Practice
Evaluation of the Cost-Effectiveness of Novel Tests in the Screening and Diagnostic Phases of Prostate Cancer Compared to Current Practice Master s Thesis in Biomedical Engineering & Mathematical Statistics
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationUrine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia
Urine Markers for Bladder Cancer Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia Disclosures Role Consultant/Speaker Grant Funding Clinical
More informationNEGATIVE BIOPSIES WITH RISING PROSTATE-SPECIFIC ANTIGEN. WHAT TO DO?
NEGATIVE BIOPSIES WITH RISING PROSTATE-SPECIFIC ANTIGEN. WHAT TO DO? *Juan Gómez Rivas, 1 Mario Alvarez-Maestro, 1 Marcin Czarniecki, 2 Stefan Czarniecki, 3 Moises Rodriguez Socarras, 4 Stacy Loeb 5 1.
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 Company Presentation Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This presentation contains forward-looking
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationTowards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time
european urology supplements 8 (2009) 97 102 available at www.sciencedirect.com journal homepage: www.europeanurology.com Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationIf you have aggressive cancer, you would want treatment in time for a cure.
Prostate cancer: PSA screening, biopsy, new technologies The treatment/cure should never be worse than the disease. If you have aggressive cancer, you would want treatment in time for a cure. What is PSA?
More informationMINERVA MEDICA COPYRIGHT
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationPSA-based Early Detection in the US:
PSA-based Early Detection in the US: What Went Wrong, and How to Screen Smarter Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops PAHO/WHO Consultation on
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More information3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD
PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive
More informationProstate Biopsy in 2017
Prostate Biopsy in 2017 Bob Djavan, MD, PhD Professor and Chairman, Department of Urology, Rudolfinerhaus Foundation Hospital,Vienna, Austria Director Vienna Urology foundation Board member Scientific
More informationCorporate Medical Policy
Corporate Medical Policy Saturation Biopsy for Diagnosis, Staging, and Management of Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: saturation_biopsy_for_diagnosis_ staging_and_management_of_prostate_cancer
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationA Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason 3+4 Prostate Cancer on Biopsy
2554 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2554-2560. doi: 10.7150/jca.20031 A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationUrine Biomarkers for Prostate Cancer Detection
Urine Biomarkers for Prostate Cancer Detection Dr. Qun Lu Professor of Anatomy and Cell Biology Director, The Wooten Laboratory Brody School of Medicine Acknowledgement of Support Funding US National Institutes
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationProstate Cancer. To screen or not to screen, that is the question
Prostate Cancer To screen or not to screen, that is the question Michael D Marcus, M.D. Assistant Professor of Urology St Louis University Chairman, Department of Surgery SSMHealth St Mary s Hospital,
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationGene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Policy Number: 2.04.111 Last Review: 04/2018 Origination: 04/2014 Next Review: 04/2019 Policy Blue Cross and Blue Shield
More informationAn Approach Using PSA Levels of 1.5 ng/ml as the Cutoff for Prostate Cancer Screening in Primary Care.
Thomas Jefferson University Jefferson Digital Commons Department of Urology Faculty Papers Department of Urology 10-1-2016 An Approach Using PSA Levels of 1.5 ng/ml as the Cutoff for Prostate Cancer Screening
More informationThe Use of Biomarkers in Prostate Cancer Screening and Treatment
Treatment Update The Use of Biomarkers in Prostate Cancer Screening and Treatment Ashley V. Alford, MD, 1 Joseph M. Brito III, MD, 2 Kamlesh K. Yadav, 3 Shalini S. Yadav, 4 Ashutosh K. Tewari, MD, 5 Joseph
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationSerum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
More informationCommercial Products Not applicable
Medical Coverage Policy Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer EFFECTIVE DATE: 02 16 2016 POLICY LAST UPDATED: 12 18 2018 OVERVIEW Various genetic
More information2/5/2014. BIOMARKERS AND PROSTATE CANCER Can new biomarkers improve clinical decision making? Samir Bidnur PGY Feb
BIOMARKERS AND PROSTATE CANCER Can new biomarkers improve clinical decision making? Samir Bidnur PGY- 3 5- Feb- 2013 Objec-ves Review the need for new biomarkers in prostate cancer management Discuss the
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationC. Stephen Farmer, II MD Urology Associates
C. Stephen Farmer, II MD Urology Associates Benign Prostate Hypertrophy Benign Prostate Hypertrophy Symptoms Hesitancy Intermittency Nocturia Post-void dribbling Dysuria Urgency Frequency Hematuria Benign
More informationProstate MRI: Screening, Biopsy, Staging, and Ablation
Prostate MRI: Screening, Biopsy, Staging, and Ablation Scott Eggener, M.D. Associate Professor of Surgery- Urologic Oncology Director- Prostate Cancer Program University of Chicago International Prostate
More informationMEDICAL POLICY SUBJECT: MAGNETIC RESONANCE IMAGING PROSTATE/MULTIPARAMETRIC MRI EFFECTIVE DATE: 06/21/18
MEDICAL POLICY SUBJECT: MAGNETIC RESONANCE IMAGING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationProstate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics
Biomedical Engineering for Global Health Lecture Fourteen Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More information